Which of my compounds have toxic liabilities?

It is estimated that about one third of all drugs fail pre-clinical or clinical testing because of potential toxicities.  Whilst animal models remain the gold standard required by international regulations there are limitations in terms of predictive power, expense, and throughput capacity.

The CXR approach

CXR Biosciences has developed a range of state of the art methodologies and technologies to determine the toxicological characteristics of compounds, and has the experience and expertise to accurately predict the relevance to man. A customised series of studies is tailor made to deliver a cost effective solution to the client's requirements, and ranges from rapid in vitro screens that can be applied to large numbers of compounds, to detailed toxicological investigations for particular compounds. Novel cutting edge technologies and approaches are continually being developed and applied, which include transcriptional profiling and CXR Biosciences’ proprietary toxicity reporter models.